Trial Profile
A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2012 Planned End Date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 04 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.